{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Kidney+Disease%2C+Secondary+Hyperparathyroidism&page=3",
    "query": {
      "condition": "Chronic Kidney Disease, Secondary Hyperparathyroidism",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 67,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Kidney+Disease%2C+Secondary+Hyperparathyroidism&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Kidney+Disease%2C+Secondary+Hyperparathyroidism&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T04:21:48.385Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00958451",
      "title": "Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Paricalcitol",
          "type": "DRUG"
        },
        {
          "name": "Ergocalciferol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Salem Veterans Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2009-07",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2011-03-24",
      "last_synced_at": "2026-10-12T04:21:48.385Z",
      "location_count": 1,
      "location_summary": "Salem, Virginia",
      "locations": [
        {
          "city": "Salem",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00958451"
    },
    {
      "nct_id": "NCT00823303",
      "title": "Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Paricalcitol",
          "type": "DRUG"
        },
        {
          "name": "Calcitriol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2009-02",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2014-08-07",
      "last_synced_at": "2026-10-12T04:21:48.385Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00823303"
    },
    {
      "nct_id": "NCT07494045",
      "title": "Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CKD Stage 3",
        "CKD Stage 4",
        "Secondary Hyperparathyroidism",
        "VDI"
      ],
      "interventions": [
        {
          "name": "CTAP101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Month to 17 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-08-05",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-12T04:21:48.385Z",
      "location_count": 5,
      "location_summary": "Kansas City, Missouri • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07494045"
    },
    {
      "nct_id": "NCT00587158",
      "title": "Oral Paricalcitol in Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Transplant; Failure, Kidney",
        "Renal Disease, End Stage",
        "Hyperparathyroidism, Secondary"
      ],
      "interventions": [
        {
          "name": "Paricalcitol",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroid Avoidance Immune Suppression Protocol",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2007-01",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2013-05-13",
      "last_synced_at": "2026-10-12T04:21:48.385Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00587158"
    },
    {
      "nct_id": "NCT03633708",
      "title": "A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Etelcalcetide",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 56,
      "start_date": "2019-04-29",
      "completion_date": "2029-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-12T04:21:48.385Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03633708"
    },
    {
      "nct_id": "NCT05832931",
      "title": "Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism",
        "End-stage Kidney Disease (ESKD)"
      ],
      "interventions": [
        {
          "name": "PLS240",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Open-Label Extension PLS240",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pathalys Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 362,
      "start_date": "2023-04-28",
      "completion_date": "2025-07-28",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-10-12T04:21:48.385Z",
      "location_count": 49,
      "location_summary": "Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more",
      "locations": [
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05832931"
    },
    {
      "nct_id": "NCT01785875",
      "title": "Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperparathyroidism, Secondary"
      ],
      "interventions": [
        {
          "name": "Etelcalcetide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 891,
      "start_date": "2013-07-31",
      "completion_date": "2015-07-01",
      "has_results": true,
      "last_update_posted_date": "2019-04-10",
      "last_synced_at": "2026-10-12T04:21:48.385Z",
      "location_count": 101,
      "location_summary": "Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 86 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01785875"
    },
    {
      "nct_id": "NCT00257920",
      "title": "A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Kidney Disease, Stage 5",
        "Secondary Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "Zemplar® injection",
          "type": "DRUG"
        },
        {
          "name": "Hectorol® injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2006-06",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2009-12-24",
      "last_synced_at": "2026-10-12T04:21:48.385Z",
      "location_count": 2,
      "location_summary": "Bellevue, Nebraska • Omaha, Nebraska",
      "locations": [
        {
          "city": "Bellevue",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00257920"
    },
    {
      "nct_id": "NCT01191762",
      "title": "Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperparathyroidism",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "sevelamer carbonate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kenneth R. Phelps, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 30,
      "start_date": "2010-04",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2016-11-01",
      "last_synced_at": "2026-10-12T04:21:48.385Z",
      "location_count": 1,
      "location_summary": "Albany, New York",
      "locations": [
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01191762"
    },
    {
      "nct_id": "NCT01439867",
      "title": "Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Hyperparathyroidism, Secondary"
      ],
      "interventions": [
        {
          "name": "Cinacalcet hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "28 Days",
        "maximum_age": "2189 Days",
        "sex": "ALL",
        "summary": "28 Days to 2189 Days"
      },
      "enrollment_count": 18,
      "start_date": "2012-06-22",
      "completion_date": "2016-06-03",
      "has_results": true,
      "last_update_posted_date": "2020-06-17",
      "last_synced_at": "2026-10-12T04:21:48.385Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01439867"
    }
  ]
}